This article is more than 5 years old. Information may no longer be current.
Inflammatory Bowel Disease: Future Directions in Treatment and Management When to Switch and When to Stop
Click Here to Manage Email Alerts
Inflammatory bowel disease is heterogeneous, so individualizing therapy based on disease type, severity, and prognosis is crucial. In this CME program, Dr. David Rubin discusses how to select initial therapy, use the treat-to-target approach, and develop strategies for nonresponders, always with a focus on the individual patient.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to summarize the benefits and limitations of available therapeutic agents for the management of inflammatory bowel disease (IBD).
To see this Education Lab activity, click here.
Overview
Author(s)/Faculty: David T. Rubin, MD
Source: Healio Gastroenterology Education Lab
Type: Mutlimedia
Articles/Items: 3
Release Date: 9/8/2016
Expiration Date: 9/8/2017
Credit Type: CME
Number of Credits: 0.25
Cost: Free
Provider: Vindico Medical Education
CME Information
Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.
Support Statement: This activity is supported by an educational grant from Receptos Inc.
Target Audience: The intended audience for the activities is gastroenterologists and other health care professionals involved in the treatment of patients with inflammatory bowel disease (IBD).